BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16114057)

  • 1. ELL binding regulates U19/Eaf2 intracellular localization, stability, and transactivation.
    Xiao W; Jiang F; Wang Z
    Prostate; 2006 Jan; 66(1):1-12. PubMed ID: 16114057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induction and growth suppression by U19/Eaf2 is mediated through its ELL-binding domain.
    Hahn J; Xiao W; Jiang F; Simone F; Thirman MJ; Wang Z
    Prostate; 2007 Feb; 67(2):146-53. PubMed ID: 17044034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FB1, an E2A fusion partner in childhood leukemia, interacts with U19/EAF2 and inhibits its transcriptional activity.
    Jiang F; Ai J; Xiao W; Wang Z
    Cancer Lett; 2007 Aug; 253(2):265-72. PubMed ID: 17395368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pirin down-regulates the EAF2/U19 protein and alleviates its growth inhibition in prostate cancer cells.
    Qiao Z; Wang D; Hahn J; Ai J; Wang Z
    Prostate; 2014 Feb; 74(2):113-20. PubMed ID: 24272884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
    Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
    Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia.
    Xiao W; Zhang Q; Habermacher G; Yang X; Zhang AY; Cai X; Hahn J; Liu J; Pins M; Doglio L; Dhir R; Gingrich J; Wang Z
    Oncogene; 2008 Mar; 27(11):1536-44. PubMed ID: 17873910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel variant form of MLL-ELL fusion transcript with t(11;19)(q23;p13.1) in chronic myelomonocytic leukemia transforming to acute myeloid leukemia.
    Kakihana K; Kubo F; Wakabayashi S; Kurosu T; Miki T; Murakami N; Miura O
    Cancer Genet Cytogenet; 2008 Jul; 184(2):109-12. PubMed ID: 18617060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor suppressor U19/EAF2 regulates thrombospondin-1 expression via p53.
    Su F; Pascal LE; Xiao W; Wang Z
    Oncogene; 2010 Jan; 29(3):421-31. PubMed ID: 19826414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of murine ELL-associated factor 2 (Eaf2) is developmentally regulated.
    Li M; Wu X; Zhuang F; Jiang S; Jiang M; Liu YH
    Dev Dyn; 2003 Oct; 228(2):273-80. PubMed ID: 14517999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate.
    Su F; Correa BR; Luo J; Vencio RZ; Pascal LE; Wang Z
    Cancer Microenviron; 2013 Dec; 6(3):247-61. PubMed ID: 23440596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXA1 modulates EAF2 regulation of AR transcriptional activity, cell proliferation, and migration in prostate cancer cells.
    Guo W; Keener AL; Jing Y; Cai L; Ai J; Zhang J; Fisher AL; Fu G; Wang Z
    Prostate; 2015 Jun; 75(9):976-87. PubMed ID: 25808853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elongation factor ELL (Eleven-Nineteen Lysine-rich Leukemia) acts as a transcription factor for direct thrombospondin-1 regulation.
    Zhou J; Feng X; Ban B; Liu J; Wang Z; Xiao W
    J Biol Chem; 2009 Jul; 284(28):19142-52. PubMed ID: 19447890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.
    Yu X; Ai J; Cai L; Jing Y; Wang D; Dong J; Pascal LE; Zhang J; Luo R; Wang Z
    Oncotarget; 2016 May; 7(20):29245-54. PubMed ID: 27058417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defective FESTA/EAF2-mediated transcriptional activation in S-II-deficient embryonic stem cells.
    Ito T; Saso K; Arimitsu N; Sekimizu K
    Biochem Biophys Res Commun; 2007 Nov; 363(3):603-9. PubMed ID: 17892859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcriptional regulation of the mouse PNRC2 promoter by the nuclear factor Y (NFY) and E2F1.
    Zhou D; Masri S; Ye JJ; Chen S
    Gene; 2005 Nov; 361():89-100. PubMed ID: 16181749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction between EAP30 and ELL is modulated by MCM2.
    Mathews A; Holland L; Yankulov K
    FEBS Lett; 2009 Nov; 583(21):3431-6. PubMed ID: 19819239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Negative feedback regulation of Wnt4 signaling by EAF1 and EAF2/U19.
    Wan X; Ji W; Mei X; Zhou J; Liu JX; Fang C; Xiao W
    PLoS One; 2010 Feb; 5(2):e9118. PubMed ID: 20161747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ELL is an HIF-1alpha partner that regulates and responds to hypoxia response in PC3 cells.
    Liu L; Ai J; Xiao W; Liu J; Wang Y; Xin D; He Z; Guo Y; Wang Z
    Prostate; 2010 May; 70(7):797-805. PubMed ID: 20166137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a genetic interaction between the tumor suppressor EAF2 and the retinoblastoma protein (Rb) signaling pathway in C. elegans and prostate cancer cells.
    Cai L; Wang D; Fisher AL; Wang Z
    Biochem Biophys Res Commun; 2014 May; 447(2):292-8. PubMed ID: 24727455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The elongation factor ELL (eleven-nineteen lysine-rich leukemia) is a selective coregulator for steroid receptor functions.
    Pascual-Le Tallec L; Simone F; Viengchareun S; Meduri G; Thirman MJ; Lombès M
    Mol Endocrinol; 2005 May; 19(5):1158-69. PubMed ID: 15650021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.